Invesco Pharmaceuticals ETF Experiences Major Drop in Short Interest

The Invesco Pharmaceuticals ETF (NYSEARCA:PJP) has reported a significant reduction in short interest, with data from January 30, 2024, showing a total of 9,581 shares sold short. This marks a substantial decline of 76.3% from the previous total of 40,386 shares as of January 15, 2024. With an average daily volume of 26,462 shares, the current short-interest ratio stands at 0.4 days, indicating that only 0.3% of the ETF’s shares are sold short.

On January 31, 2024, PJP’s stock traded up by $0.46, reaching a price of $109.57. A total of 66,923 shares were exchanged during the trading session, slightly below its average volume of 70,644 shares. The ETF’s performance metrics reveal a 50-day moving average price of $105.99 and a 200-day moving average price of $98.10. Over the past year, the stock has experienced a low of $72.25 and a high of $110.54, while the ETF holds a market capitalization of $418.56 million and a P/E ratio of 15.59.

Institutional Investment Activity

Recent adjustments by institutional investors and hedge funds have influenced the Invesco Pharmaceuticals ETF. For instance, Flagship Harbor Advisors LLC increased its holdings by 1.8% in the fourth quarter, owning 6,049 shares valued at $632,000 after acquiring an additional 105 shares. Similarly, IFP Advisors Inc raised its position by 31.3%, now holding 440 shares worth $46,000 following the purchase of another 105 shares.

AE Wealth Management LLC also expanded its stake by 21.5% during the second quarter, bringing its total to 717 shares worth $57,000. Furthermore, J.W. Cole Advisors Inc increased its holdings by 4.7% in the fourth quarter to own 2,910 shares valued at $304,000. Northwestern Mutual Wealth Management Co. enhanced its position by 5.7% during the third quarter, now owning 2,791 shares worth $258,000 after adding 150 shares.

Understanding the Invesco Pharmaceuticals ETF

The Invesco Pharmaceuticals ETF is designed to track the performance of the Dynamic Pharmaceuticals Intellidex Index. This non-diversified fund evaluates companies based on multiple investment criteria, including growth potential, stock valuation, investment timing, and associated risk factors. The index comprises stocks from 30 U.S. pharmaceutical companies engaged in various aspects of the pharmaceutical industry, including research, development, manufacturing, and distribution of drugs.

As the market continues to respond to changes in short interest and institutional investment strategies, the Invesco Pharmaceuticals ETF stands as a noteworthy option for investors interested in the pharmaceutical sector.